The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Subscribe To Our Newsletter & Stay Updated
